Genmab ADR [GMAB] stock is trading at $22.15, down -0.18%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GMAB shares have gain 5.48% over the last week, with a monthly amount glided 0.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On August 20, 2024, downgrade downgraded it’s rating to Neutral. RBC Capital Mkts upgraded its rating to a Outperform. BMO Capital Markets upgraded its rating to a Outperform and raised its price target to $48 on February 23, 2024. Citigroup downgraded its rating to Sell for this stock on January 22, 2024. In a note dated December 06, 2023, UBS upgraded an Buy rating on this stock.
Genmab ADR [GMAB] stock has fluctuated between $19.85 and $32.56 over the past year. Currently, Wall Street analysts expect the stock to reach $38.5 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $22.15 at the most recent close of the market. An investor can expect a potential return of 73.81% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
Genmab ADR [NASDAQ:GMAB] reported sales of 2.87B for the trailing twelve months, which represents a growth of 17.81%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.33%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.15 and Total Capital is 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.02 points at the first support level, and at 21.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.26, and for the 2nd resistance point, it is at 22.36.
Ratios To Look Out For
For context, Genmab ADR’s Current Ratio is 5.17. Also, the Quick Ratio is 5.15, while the Cash Ratio stands at 1.38. Considering the valuation of this stock, the price to sales ratio is 4.90, the price to book ratio is 2.94 and price to earnings (TTM) ratio is 21.34.
